Neurocrine’s Phase II Results In Schizophrenia Mixed, But Enough To Move To Phase III

 
• By Joseph Haas
  
PS1911_Clinical Trial_1444423208_1200.jpg
Neurocrine's Phase II schizophrenia trial yielded signs of efficacy but mixed results

More from Clinical Trials

More from R&D